🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareI just want to eat pizza again is that too much to ask

I just want to eat pizza again is that too much to ask

TomFromTexas Fri, Jan 9, 2026 at 4:22 PM 31 replies 1,064 viewsPage 1 of 7
TomFromTexas
Member
645
2,890
May 2024
Austin, TX
Jan 9, 2026 at 4:22 PM#1

My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my material.

The bit I cannot resolve on my own is how to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases.

Not looking for reassurance. Looking for the part I have got wrong.

28 23PharmD_Rodriguez, julia.endo, JessicaM_2024 and 25 others
Reply Quote Save Share Report
LibrarianMeg
Senior Member
1,678
7,890
Mar 2024
Baltimore, MD
Jan 9, 2026 at 4:30 PM#2

Taking the question as asked, rather than the general version of it. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

27 22PharmD_Rodriguez, julia.endo, JessicaM_2024 and 24 others
Reply Quote Save Share Report
wanda_boise
Member
412
1,890
Aug 2024
Boise, ID
Jan 9, 2026 at 4:38 PM#3
LibrarianMeg said:
The gap between trial results and real-world results is consistent and it is not fraud.

Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational studies can provide useful evidence.

A recent PSM study of 25,000 GLP-1 users vs matched controls showed reduced stroke risk (HR 0.82) over 5 years of follow-up[1].

These results complement the RCT data and suggest the benefits translate to real-world populations.

References:
[1] Registry-based cohort study, pre-print 2024.
26 21pam_columbus, nick_SD_fit, ben_calgary and 23 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
SteveThurs
Member
523
2,345
Sep 2024
Wisconsin
Online
Jan 9, 2026 at 4:46 PM#4
TomFromTexas said:
My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Can confirm the pattern TomFromTexas describes. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.

Last edited: Jan 9, 2026 at 8:46 PM
25 20DoseLogDan, SleepFixSam, PurityPaulOR and 22 others
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Jan 9, 2026 at 5:27 PM#5

From the other side of the consultation, briefly.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

24 19hank_denver, carlos_SATX, sophie_paris and 21 others
Reply Quote Save Share Report
1237

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register